REFERENCES
1. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Sazonova D.V., et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (2): 104–23. DOI: https://doi.org/10.14341/DM13035 (in Russian)
2. Dedov I.I., Shestakova M.V., Mayorov A.Y. (eds). Algorithms of specialized medical care for patients with diabetes mellitus. 11th issue. Sakharniy diabet [Diabetes Mellitus]. 2023; 26 (2S): 1–231. DOI: https://doi.org/10.14341/DM13042 (in Russian)
3. Cavender M.A., Steg P.G., Smith S.C. Jr, et al.; REACH Registry Investigators. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation. 2015; 132 (10): 923–31. DOI: https://doi.org/10.1161/CIRCULATIONAHA.114.014796
4. Rorth R., Jhund P.S., Mogensen U.M., et al. Risk of incident heart failure in patients with diabetes and asymptomatic left ventricular systolic dysfunction. Diabetes Care. 2018; 41 (6): 1285–91. DOI: https://doi.org/10.2337/dc17-2583
5. Guglin M., Lynch K., Krischer J. Heart failure as a risk factor for diabetes mellitus. Cardiology. 2014; 129 (2): 84–92. DOI: https://doi.org/10.1159/000363282
6. Benjamin E.J., Muntner P., Alonso A., et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019; 139 (10): e56–528. DOI: https://doi.org/10.1161/CIR.0000000000000659
7. Abbott R.D., Donahue R.P., Kannel W.B., Wilson P.W.F. The impact of diabetes on survival following myocardial infarction in men vs women: the Framingham Study. JAMA. 1988; 260 (23): 3456–60. DOI: https://doi.org/10.1001/jama.1988.03410230074031
8. Thomas M.C., Cooper M.E., Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol. 2016; 12 (2): 73–81. DOI: https://doi.org/10.1038/nrneph.2015.173
9. Birkeland K.I., Bodegard J., Eriksson J.W., et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020; 22 (9): 1607–18. DOI: https://doi.org/10.1111/dom.14074
10. Hillege H.L., Nitsch D., Pfeffer M.A., et al.; Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006; 113 (5): 671–8. DOI: https://doi.org/10.1161/CIRCULATIONAHA.105.580506
11. Reznik E.V., Nikitin I.G. Cardiorenal syndrome in patients with chronic heart failure as a stage of the cardiorenal continuum (part I): definition, classification, pathogenesis, diagnosis, epidemiology. Arkhiv vnutrenney meditsiny [Archive of Internal Medicine]. 2019; 9 (1): 5–22. DOI: https://doi.org/10.20514/2226-6704-2019-9-1-5-22 (in Russian)
12. Pieske B., Tschöpe C., de Boer R.A., et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019; 40 (40): 3297–317. DOI: https://doi.org/10.1093/eurheartj/ehz641
13. Russian Society of Cardiology (RSC). 2020 Clinical practice guidelines for chronic heart failure. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2020; 25 (11): 311–74. DOI: https://doi.org/10.15829/1560-4071-2020-4083 (in Russian)
14. MacDonald M.R., Petrie M.C., Varyani F., et al.; CHARM Investigators. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008; 29 (11): 1377–85. DOI: https://doi.org/10.1093/eurheartj/ehn153
15. Tan Y., Zhang Z., Zheng C., et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020; 17 (9): 585–607. DOI: https://doi.org/10.1038/s41569-020-0339-2
16. Boonman-de Winter L.J.M., Rutten F.H., Cramer M.J.M., et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012; 55: 2154–62. DOI: https://doi.org/10.1007/s00125-012-2579-0
17. Escalada J. SGLT2 inhibitors and the cardiorenal continuum: a paradigm shift in the treatment of patients with T2D. Diabetes Ther. 2022; 13 (suppl 1): 1–3. DOI: https://doi.org/10.1007/s13300-022-01281-5
18. Seferović P.M., Petrie M.C., Filippatos G.S., et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018; 20 (5): 853–72. DOI: https://doi.org/10.1002/ejhf.1170
19. Shehadeh A., Regan T.J. Cardiac consequences of diabetes mellitus. Clin Cardiol. 1995; 18 (6): 301–5. DOI: https://doi.org/10.1002/clc.4960180604
20. Devereux R.B., Roman M.J., Paranicas M., et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000; 101 (19): 2271–6. DOI: https://doi.org/10.1161/01.cir.101.19.2271
21. Galderisi M., Anderson K.M., Wilson P.W., Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991; 68 (1): 85–9. DOI: https://doi.org/10.1016/0002-9149(91)90716-x
22. Regan T.J., Lyons M.M., Ahmed S.S., et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest. 1977; 60 (4): 884–99. DOI: https://doi.org/10.1172/JCI108843
23. Wang M., Li Y., Li S., Lv J. Endothelial dysfunction and diabetic cardiomyopathy. Front Endocrinol (Lausanne). 2022; 13: 851941. DOI: https://doi.org/10.3389/fendo.2022.851941